Stocks Health care DCOY
NASDAQ · Health careDecoy Therapeutics Inc. (DCOY)
It posted a net loss of $14.4M. In fiscal 2025 capital spending exceeded operating cash flow by $5.4M. At June 30, 2026 it held $8.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Decoy Therapeutics Inc.
- Net worth
- Decoy Therapeutics Inc. has a market value (market cap) of $714.2K at the latest share price, and shareholders' equity of $4.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2022 revenue was $0 (-100.0% year on year), with a net loss of $31.6M.
- Cash flow
- In fiscal 2025 operations used $4.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Decoy Therapeutics Inc.'s next report is expected around November 16, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Decoy Therapeutics Inc. does
Decoy Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker DCOY.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$12.5M | -$129.10 | -$5.4M |
| 2024 | n/a | -$5.6M | -$69.54 | -$4.5M |
| 2023 | n/a | -$12.5M | -$369.20 | n/a |
| 2022 | $0 | -$31.6M | -$1,430.64 | n/a |
| 2021 | $1.8M | -$12.8M | -$742.24 | -$10.2M |
| 2020 | $5.2M | -$7.4M | -$1,197.17 | -$10.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Dividends
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2020 | n/a | $0 | n/a |
| 2019 | n/a | $133.6K | n/a |
| 2018 | n/a | $0 | n/a |
Latest SEC filings
What Decoy Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 23, 2026Material agreement8-KDecoy Therapeutics raised approximately $3.85 million in gross proceeds through a warrant inducement transaction.
- September 15, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue was $227.6K; diluted EPS -$4.46 versus -$81.21.
- August 4, 2026Proxy statement DEF 14A
- August 4, 2026Additional proxy material DEFA14A
- July 24, 2026Preliminary proxy statement PRE 14A
- July 15, 2026
- July 10, 2026IPO registration S-1
- June 29, 2026
Insider trades
What the people running Decoy Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 10 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 31, 2026 | Lieber Jonathan IDirector | Received as pay | 2,000 | - |
| August 31, 2026 | Pierce Frederick IIChief Executive Officer | Received as pay | 33,455 | - |
| August 31, 2026 | Hanish Arnold CDirector | Received as pay | 3,000 | - |
| August 31, 2026 | Rosenblum Mark JChief Financial Officer | Received as pay | 9,682 | - |
| August 31, 2026 | Lammers PaulDirector | Received as pay | 2,000 | - |
| August 31, 2026 | McVicar William K.Director | Received as pay | 3,000 | - |
| August 31, 2026 | Burleson TessDirector | Received as pay | 2,000 | - |
| August 31, 2026 | Hibner Barbara LouiseChief Scientific Officer | Received as pay | 4,216 | - |
Who owns DCOY
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Armistice Capital, LLC13G, passive with 1 related filers | 9.99% | August 14, 2026 |
| CVI Investments, Inc.13G, passive with 1 related filers | 9.9% | February 17, 2026 |
Largest institutional holders
Insiders
10 insiders reported holding 73,748 shares in total, about $80.4K at the last price.
| Holder | Shares |
|---|---|
| Pierce Frederick IIChief Executive Officer | 34,844 |
| Rosenblum Mark JChief Financial Officer | 11,363 |
| Hanish Arnold CDirector | 8,4185,000 held indirectly |
| Hibner Barbara LouiseChief Scientific Officer | 4,216 |
| Marschel Peter KlausChief Business Officer | 3,900 |
| McVicar William K.Director | 3,002 |
| Burleson TessDirector | 2,002 |
| Lieber Jonathan IDirector | 2,002 |
| Lammers PaulDirector | 2,001 |
| Gauthier Patricia G.Director | 2,000 |
Questions about DCOY
What does Decoy Therapeutics Inc. do?
Decoy Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as DCOY. Its shares trade on NASDAQ under the ticker DCOY.
What is Decoy Therapeutics Inc.'s net worth?
Decoy Therapeutics Inc. has a market value (market cap) of $714.2K at the latest share price, and shareholders' equity of $4.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Decoy Therapeutics Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $14.4M.
When did Decoy Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 23, 2026.
When is Decoy Therapeutics Inc.'s next earnings report?
Decoy Therapeutics Inc.'s next report is expected around November 16, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare DCOY with
Follow DCOY
Get an email when Decoy Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Decoy Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.